Abstracts tagged "patient outcomes and vasculitis"

Abstract Number: 2723 • 2018 ACR/ARHP Annual Meeting
Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy
Peter Rutherford¹, Dieter Goette¹, James O`Donoghue² and Xierong Liu², ¹Medical Affairs, Vifor Pharma, Zurich, Switzerland, ²Elma Research, London, United Kingdom
Background/Purpose: ANCA-associated vasculitis (AAV) leads to both acute illness and a long-term condition in which the disease remits and relapses. Therapy is often complex and…
Abstract Number: 2724 • 2018 ACR/ARHP Annual Meeting
Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU
Peter Rutherford¹, Dieter Goette¹, Melinda Stamm² and Xierong Liu², ¹Medical Affairs, Vifor Pharma, Zurich, Switzerland, ²Elma Research, London, United Kingdom
Background/Purpose: Aims of therapy in incident AAV patients include ensuring rapid diagnosis, assessment of comorbidity, disease activity, and vasculitis damage before commencing treatment with a…
Abstract Number: 751 • 2013 ACR/ARHP Annual Meeting
Fatigue, Pain, and Functional Disability Among Patients With Vasculitis
Antoine G. Sreih^1,2, Narender Annapureddy³ and Osama Elsallabi⁴, ¹Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Medicine, Creighton University, Omaha, NE
Background/Purpose: Vasculitis is a heterogeneous group of diseases often resulting in severe morbidity affecting patients’ quality of life. These morbidities are generally attributed to disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].